p53 tumour-suppressor gene in non-small-cell lung cancer with neoadjuvant therapy

@article{Junker2000p53TG,
  title={p53 tumour-suppressor gene in non-small-cell lung cancer with neoadjuvant therapy},
  author={K. Junker and T. Wiethege and K. M{\"u}ller and M. Thomas},
  journal={Journal of Cancer Research and Clinical Oncology},
  year={2000},
  volume={126},
  pages={238-245}
}
  • K. Junker, T. Wiethege, +1 author M. Thomas
  • Published 2000
  • Medicine
  • Journal of Cancer Research and Clinical Oncology
  • Abstract In a phase II study for optimizing therapeutic management of locally advanced non-small-cell lung cancer the prognostic and therapeutic relevance of the p53 status was investigated. Biopsy or mediastinoscopy samples, collected prior to neoadjuvant chemoradiotherapy and corresponding resection specimens, were analysed immunohistochemically (CM1 antiserum) for p53 accumulation and molecular biologically (polymerase chain reaction/single-strand conformation polymorphism) for p53 mutations… CONTINUE READING

    Figures, Tables, and Topics from this paper.

    p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer
    30
    Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer.
    9

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 36 REFERENCES
    Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma.
    55
    Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor.
    142
    Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer.
    250